Skip to main content
NCBI home page
Journal of Clinical Medicine logoLink to Journal of Clinical Medicine
. 2023 Jan 30;12(3):1088. doi: 10.3390/jcm12031088

Podocyte Infolding Glomerulopathy: A Case Series Report and Literature Review

Yunlin Feng 1,2,3,†, Wei Wang 1,2,†, Yurong Zou 1,2, Tingyu Chen 4, Wei Wang 1,2, Guisen Li 1,2, Amanda Y Wang 3,5,6, Ping Zhang 1,2,*
Editor: Ernesto Paoletti
PMCID: PMC9918010  PMID: 36769735

Abstract

Background: Podocyte infolding glomerulopathy (PIG) is a peculiar and very rare manifestation in renal pathology. Its underlying pathogenesis mechanism and clinical characteristics remain unclear due to sparse reports. Objective: To further elucidate the clinical profile of PIG by carefully reporting our four cases and a comprehensive review of cases in the literature. Methods: This study retrospectively reviewed four cases of PIG from 2010 to 2022 in our centre. Clinical and pathological profiles were reported. PIG cases in the literature were searched in the MEDLINE database and analysed together with our cases. Results: Four cases of PIG identified from our centre and 40 cases from the current literature were reported. The pooled analysis of these 44 cases indicated 79.5% (35/44) were females, 93.2% (41/44) were East Asians, and 63.6% (28/44) were reported in Japan. The average age was 42.0 ± 12.5 years old. The average amount of proteinuria at the time of renal biopsy was 3.06 ± 3.2 g/day. The most reported comorbidities were connective tissue diseases, mainly systemic lupus erythematosus, and 20.5% (9/44) of the cases did not have any contaminant disease. Most of the cases (81.8%, 36/44) had been treated with immunosuppressants, of which a combination of corticosteroids and one other type of immunosuppressant was most commonly reported. In addition, 45.4% (20/44) and 34.1% (15/44) of the cases had achieved complete response and partial response, respectively, after treatment. Whole exosome sequencing indicated mutations in the INF2 gene. Conclusions: PIG is a rare condition and seen in relatively younger populations, often associated with connective tissue diseases clinically and one or two other glomerulopathies histologically. The outcomes following immunosuppressive treatment are relatively good. Mutations in INF2 might be involved in the development of PIG; however, the implications of these results need to be investigated.

Keywords: podocyte infolding, glomerulopathy, case series, INF2, literature review

1. Introduction

Podocyte infolding glomerulopathy (PIG) is a very rare phenomenon that was first reported as a unique pathological manifestation in 1992 [1] in Japan and officially proposed as a new disease entity in 2008 by the Japanese Society of Nephrology in 2008 [2]. PIG is characterized by peculiar microstructures of microspheres, microtubules, or both within the thickened glomerular basement membrane (GBM), accompanied by podocyte infolding [2]. It is not included as a separate category in the current classification of glomerular diseases. Thus far, most reported cases have been in East Asians.

The underlying pathogenesis mechanism of PIG remains unclear. Successive pathology sections analysis indicated that PIG might be a continuous process of podocyte processes from primary infolding to bubbling [2]. The initiation factor of the primary infolding is not clear. The only gene reported to be involved in PIG so far is SMARCAL1, detected by whole exosome sequencing in a child with Schimke immune-osseous dysplasia (SIOD) [3]. However, the contributions of these mutations to the development of PIG were unclear.

The clinical features are highly diversified in PIG. It has been reported that PIG is associated with other diseases, mostly connective tissue diseases, including systemic lupus erythematosus (SLE) and Sjogren Syndrome (SS) [4,5,6,7]. However, there are also cases of PIG that were not associated with any disease entity [2,8,9]. Whether PIG is a new disease entity or just a specific renal pathological finding of coexisting diagnoses remain controversial.

To improve our understating of PIG, we reported here the largest PIG case series study from a single center thus far and comprehensively reviewed the reported cases in the literature alongside our case series.

2. Case Presentation

2.1. Case 1

This patient was a 26-year-old lady, without a known history, who presented with intermittent edema in both lower extremities for one month and denied any accompanying symptoms. Physical examination on admission indicated no remarkable findings except for mild pitting edema in both legs. Remarkable laboratory investigations at this admission were as follows: WBC 12.60 × 109/L, HGB 123 g/L, PLT 161 × 109/L, proteinuria 2.74 g/day, hematuria (−), serum creatinine (Cr) 56 μmol/L, complement C3 0.96 g/L, and total cholesterol (TC) 5.14 mmol/L. All autoimmune antibodies tested negative. A renal biopsy was done on the third day after admission. Immunofluorescence (IF) staining was positive for IgG and IgM in the capillary walls and mesangial regions (Figure 1A,B) and negative for subtypes of IgG and PLA2R antibodies. Light microscopy found global glomerulosclerosis in 2/15 glomeruli, segmental sclerosis with synechial attachment to Bowman’s capsule in 7/15 glomeruli, mild mesangial matrix expansion, and diffuse thickening of glomerular basement membrane (GBM) (Figure 1C). Marked vacuolar degeneration and granular degeneration in renal tubular epithelial cells and mild interstitial fibrosis and tubular atrophy (<5%) were also noticed. Electron microscopy found thickening of the GBM, diffuse podocyte foot process effacement, and prominent microspheres forming clusters within the GBM (Figure 1D). She was diagnosed with focal segmental glomerular sclerosis (FSGS), membranous nephropathy, and PIG. Corticosteroid therapy was prescribed, starting with 50 mg of prednisone daily. Her proteinuria began to decrease after 2 months and remained around 1 g/day. The prednisone was tapered gradually from the third month and stopped at the sixth month. Eighty milligrams of Valsartan daily was prescribed afterward. Her proteinuria remained in the range of 0.7–1.2 g/day, and her serum Cr remained normal.

Figure 1.

Figure 1

Open in a new tab

Representative pathological images of renal biopsy specimen form Case 1. Note: IF staining was positive for IgM (A) and IgG (B) in capillary walls and mesangial regions. Light microscopy indicated mild mesangial matrix expansion and diffuse thickening of GBM ((C), PASM + Masson, 400×). Electron microscopy showed thickening of the GBM, diffuse podocyte foot process effacement, and prominent microspheres forming clusters (red arrow) within the GBM ((D), 20,000×).

2.2. Case 2

This patient was a 47-year-old gentleman, without a known history, who presented with edema in both lower extremities for more than 10 days. He complained of progressive edema starting from both ankles to his knees. Foamy urine was also noticed. At admission, physical examination only found pitting edema in both legs. Remarkable lab investigations at this admission were as follows: WBC 9.25 × 109/L, HGB 163 g/L, PLT 280 × 109/L, proteinuria 9.96 g/day, hematuria (−), urine albumin-to-creatinine 5277.5 μg/mg, Cr 94.4 μmol/L, C3 0.95 g/L, and TC 6.01 mmol/L. All serum autoimmune antibodies tested negative. The result of the anti-PLA2R antibody was also negative. A renal biopsy was done on the third day after admission. IF staining was positive for IgG in the capillary walls (Figure 2A) and negative for IgM, IgA, subtypes of IgG, and PLA2R. Light microscopy found segmental sclerosis with podocyte dysplasia in 3/14 glomeruli, marked hyperplasia of overlying epithelial cells in 2/14 glomeruli, and diffuse thickening of GBM (Figure 2B). Mild interstitial fibrosis and tubular atrophy (<5%) was also noticed. Electron microscopy found diffuse podocyte foot process effacement, multiple podocyte infolding, and prominent microspheres forming clusters within the GBM (Figure 2C). The diagnosis was FSGS and PIG. His treatment included 30 mg of prednisone daily and 1 mg of tacrolimus twice daily. The proteinuria began to decrease after two months and then remained in the range of 1.2–1.9 g/day. The prednisone was tapered gradually from the third month and stopped at the end of the seventh month. Tacrolimus still continued at the time of this report. His serum Cr was normal throughout the follow-up period.

Figure 2.

Figure 2

Open in a new tab

Representative pathological images of renal biopsy specimen form Case 2. Note: IF staining was positive for IgG (A) in capillary walls. Light microscopy showed segmental sclerosis with podocyte proliferation in 3/14 glomeruli and diffuse thickening of GBM ((B), PASM + Masson, 400×). Electron microscopy showed diffuse podocyte foot process effacement, multiple podocyte infolding (blue arrow), and prominent microspheres forming clusters (red arrow) within the GBM ((C), 20,000×).

2.3. Case 3

This patient was a 48-year-old lady with a history of SLE for 20 years who presented with edema in both lower extremities for one week. After the diagnosis of SLE, she had been initially treated with prednisone and mycophenolate mofetil (MMF) for five years, which was then changed to prednisone and tacrolimus. She claimed having a renal biopsy 10 years ago, but the detailed results were unavailable. At this admission, she was receiving 10 mg of prednisone daily, 1.0 mg of tacrolimus twice daily, 100 mg of hydroxychloroquine, and 80 mg of valsartan daily. Physical examination indicated mild edema in both lower extremities and old-standing butterfly erythematosus on both cheeks. Remarkable laboratory investigations at this admission were as follows: WBC 2.31 × 109/L, HGB 105 g/L, PLT 119 × 109/L, proteinuria 4.37 g/day, hematuria (−), urine albumin-to-creatinine 5967.6 μg/mg, Cr 59.3 μmol/L, C3 0.727 g/L, ANA 1:100 (+), anti-SSA-Ab (+++), and anti-Ro52-Ab (+++). A repeat renal biopsy was done on the fourth day after admission. IF staining was positive for IgA and IgM in the mesangial regions (Figure 3A,B) and PLA2R in the capillary walls and negative for IgG and subclass IgG. Light microscopy found global glomerulosclerosis in 6/20 glomeruli, segmental sclerosis with synechial attachment to Bowman’s capsule in 2/20 glomeruli, mild mesangial matrix expansion, and diffuse thickening of GBM (Figure 3C). Focal interstitial fibrosis and tubular atrophy (about 15%) was also noticed. Electron microscopy found diffuse podocyte foot process effacement and prominent microspheres within the GBM (Figure 3D). The diagnosis was membranous nephropathy and PIG. The patient was then treated with 360 mg of belimumab once a month based on her existing combination therapy of prednisone and tacrolimus. Her proteinuria began to decrease from 5.43 g/day at discharge to 0.91 g/day after one month and remained in the range of 0.9–1.4 g/day for eight months, but it was gradually increased to 2.0–3.8 g/day afterwards. The triple regimen continued at this report. Her serum Cr was normal throughout the follow-up period.

Figure 3.

Figure 3

Open in a new tab

Representative pathological images of renal biopsy specimen form Case 3. Note: IF staining was positive for IgM and IgA in mesangial regions (A,B). Light microscopy indicated segmental sclerosis with synechial attachment to Bowman’s capsule in 2/20 glomeruli, mild mesangial matrix expansion, and diffuse thickening of GBM ((C), PASM + Masson, 400×). Electron microscopy found diffuse podocyte foot process effacement and prominent microspheres (red arrow) in the GBM ((D), 20,000×).

2.4. Case 4

This patient was a 57-year-old lady, without a known history, who presented with intermittent edema in both lower extremities for more than two months. She denied any other symptoms. Physical examination at admission indicated mild edema in both lower extremities. Remarkable lab investigations at this admission were as follows: WBC 5.09 × 109/L, HGB 137 g/L, PLT 164 × 109/L, proteinuria 3.54 g/day, hematuria (−), serum Cr 33.3 μmol/L, serum ALB 26.8 g/L, C3 0.91 g/L, ANA 1:100 (+), anti-SSA-Ab (+), and anti-AHA-Ab (+). A renal biopsy was done on the third day after the admission. IF staining was nonspecific for IgG, IgA, IgM, C3, C1q, and all subtypes of IgG and PLA2R. Light microscopy found mild mesangial matrix expansion and mild thickening of GBM, supporting mild glomerular abnormality (Figure 4A). Scattered interstitial fibrosis and tubular atrophy (about 5%) was also noticed. Electron microscopy showed diffuse podocyte foot process effacement, mild podocyte infolding, and prominent microspheres within the GBM (Figure 4B). The diagnosis was mild mesangial proliferative glomerulopathy and PIG. The patient was initially treated with 45 mg of prednisone daily. Her proteinuria began to decrease from 4.2 g/day at discharge to 0.48 g/day after two months. The prednisone was tapered gradually from the third month and stopped at the eighth month. Her proteinuria increased again to 4 g/day after one year. The patient was then treated with 10 mg of prednisone daily and 1.0 mg of tacrolimus twice daily to date. Her proteinuria was maintained in the range of 2.2–3.2 g/day afterwards. Her serum Cr was normal throughout the follow-up period.

Figure 4.

Figure 4

Open in a new tab

Representative pathological images of renal biopsy specimen form Case 4. Note: Light microscopy showed mild mesangial matrix expansion and mild thickening of GBM ((A), PASM + Masson, 400×). Electron microscopy showed diffuse podocyte foot process effacement, mild podocyte infolding, and prominent microspheres (red arrow) within the GBM ((B), 50,000×).

2.5. Whole Exosome Sequencing Results

Whole exosome sequencing of three of these four patients indicated mutations in the INF2 gene. All single nucleotide polymorphisms (SNPs) and insertion–deletion mutations (INDELs) were filtered to retain only variants classified as “PASS”. The retained variants were loaded into the R environment (v4.2.0; R Foundation for Statistical Computing, Vienna, Austria) and then visualized using the lolliplot function, described previously [10], using a Bioconductor package trackViewer (version 1.32.1; Bioconductor, Boston, MA, USA) (Figure 5). Among all SNPs and INDELs, the third mutation p.420_424del, a non-frameshift deletion located in exon8, was a harmful mutation and labelled with a red circle. The underlying meaning of these findings were to be investigated due to the small sample size of this study.

Figure 5.

Figure 5

Open in a new tab

Lolliplot illustrating the mutation profile in INF2 based on the whole exosome sequencing results of the patients. Note: All SNPs and INDELs in INF2 were plotted. The numbers inside the circle represented the mutation order. The start and end positions were indicated on the horizontal axis. All exons were filled in mistyrose. The upstream and downstream 2K regions were coloured with dark grey and light grey, respectively. Harmful mutations were represented with red circles, while harmless mutations were represented with black circles.

2.6. Literature Review

A comprehensive literature review on PIG identified 40 cases (see Section S1 in Supplementary Materials). All of them were included in the pool analysis alongside the four cases being reported from our center. The detailed characteristics of clinical and histological profiles of these 44 cases are shown in Table 1 and Table 2, respectively.

Table 1.

Characteristics of clinical profiles of PIG cases reported in the literature and in this case series.

Case No Sex Race Country Age Comorbidity Lab Investigations at Renal Biopsy Treatment
Cr (μmol/L) Proteinuria * Hematuria Therapy Response
1 [3] M Asian Japan 31 SLE 168.0 0.5 g/day Absent PSL (20 mg Qd) CR
2 [3] F Asian Japan 37 SLE 106.1 1 g/day Absent PSL (20 mg Qd), MMF CR after 6 m
3 [3] F Asian Japan 40 SLE 44.2 1.5 g/day NR PSL NR
4 [3] F Asian Japan 30 SLE 44.2 1.6 g/day Mild PSL (pulsex3) CR after 1 m
5 [3] F Asian Japan 61 SLE, Takayasu’s arteritis 79.6 1.7 g/day Absent PSL (40 mg Qd), CsA PR after 7 y
6 [3] F Asian Japan 29 SLE, hydronephrosis due to lupus cystitis 61.9 1.6 g/day Absent PSL (20 mg Qd) PR after 5 y
7 [2] F Asian Japan 46 SLE, hydronephrosis due to lupus cystitis 44.2 0.6 g/day Absent PSL (15 mg Qd) PR after 2 y
8 [2] F Asian Japan 27 SLE 35.4 2.7 g/day Absent PSL (30 mg Qd), MMF CR after 6 m
9 [2] M Asian Japan 53 SLE, bilateral urethral stone 79.6 3.1 g/day Present PSL (30 mg Qd) CR after 8 m
10 [2] F Asian Japan 23 SLE 44.2 1.8 g/day Present PSL (40 mg Qd) CR after 5 y
11 [2] F Asian Japan 31 SLE 79.6 0.5 g/day Absent PSL (20 mg Qd) CR
12 [2] F Asian Japan 24 SLE, SS 53.0 6.0 g/day Absent PSL (pulsex3) CR after 9 w
13 [2] M Asian Japan 49 PBC, SS, cystitis, finally SLE 97.2 2.2 g/day Absent ARB, PSL (40 mg Qd) CR after 9 y
14 [2] F Asian Japan 20 SLE? 123.8 1.4 g/day Absent PSL (40 mg Qd) CR
15 [2] F Asian Japan 47 RA, pSS 53.0 1.3 g/day Absent ARB, PSL (20 mg Qd) PR
16 [2] F Asian Japan 51 pSS 53.0 3.7 g/day Absent PSL (40 mg Qd) CR after 1 m
17 [2] F Asian Japan 30 MCTD 79.6 0.3 g/day Absent PSL (15 mg Qd) NR
18 [2] F Asian Japan 54 Basedow’s disease 221.0 6.0 g/day Absent - PR after 3 m
19 [2] F Asian Japan 57 Hypothyroidism, chronic thyroiditis 53.0 0.3 g/day Absent - CR after 2 m
20 [2] M Asian Japan 45 Absent 61.9 2.6 g/day Absent PSL (50 mg Qd) PR after 2 m
21 [2] F Asian Japan 42 Ovarian mature teratoma 68.1 7.5 g/day Present ARB PR after 1 m
22 [2] F Asian Japan 69 Absent 79.6 1.6 g/day Absent - PR after 1 m
23 [2] M Asian Japan 46 HBV infection 106.1 4.0 g/day Absent Diuretics PR
24 [2] M Asian Japan 59 Tumor lysis syndrome 450.8 0.6 g/day Absent PSL (pulsex3) NR
25 [2] F Asian Japan 45 Absent 70.7 1.5 g/day Absent PSL (30 mg Qd) CR after 1 y
26 [3] M Asian China 4 SIOD Normal 3.7 g/day NR P, tacrolimus, ACEI Normal renal function
27 [4] F Asian China 61 SLE, benign ovarian tumor, EBV infection 75.1 2.1 g/day Present HCQ, ARB, PSL (40 mg Qd), CTX PR
28 [5] F Asian India 45 UCTD 145.9 5.8 g/day Present High dose PSL, MMF, RTX PR
29 [6] F Asian China 33 UCTD 36.2 2.1 g/day Absent NR NR
30 [7] F Asian China 27 pSS 168.2 0.6 g/day Absent PSL (48 mg Qd), HCQ Progression
31 [7] F Asian China 23 SLE 47.1 16.8 g/day Present PSL (40 mg Qd), HCQ PR
32 [8] F Asian Japan 14 Absent 48.6 2.35 g/day Absent PSL (40 mg Qd) CR after 9 m
33 [9] F Asian South Korea 44 Absent 39.8 PCR = 67.1/88.29 mg/mg NR PSL (10 mg Qd) CR after 3 m
34 [11] F Asian Canada 52 Prior HBV infection with immunity 61 uACR = 1600 mg/mol Present ARB, P (1 mg/kg, Qd), spironolactone PR, worsened after stopping P
35 [12] F Asian China 52 pSS, Hashimoto’s thyroiditis NR NR NR NR NR
36 [13] M Asian Japan 79 MM 113.2 1.4 g/day Absent PSL (20 mg Qd) PR, but death after 2 m
37 [14] F Latin American Caucasian Argentina 38 SLE Normal NS range proteinuria NR CO + CTX Good response, but relapsed
38 [15] F Asian Japan 35 Scleroderma NR NR NR NR NR
39 [16] F NR USA 60 Absent 61.9 7.3 g/day Absent RTX PR
40 [17] F Caucasian Germany 56 RA 386.3 uACR = 6200 mg/g Absent High hose P + RTX CR
41 F Asian China 26 Absent 82.3 2.74 g/day Present Prednisone (50 mg Qd, tapered to stop) PR
42 M Asian China 47 Absent 94.4 9.96 g/day Absent Prednisone (30 mg Qd) + tacrolimus (1 mg Bid) PR
43 F Asian China 48 SLE 59.3 5.4 g/day Absent Prednisone (30 mg Qd) + tacrolimus (1 mg Bid) ± Belimumab (10 mg/kg/w) PR
44 F Asian China 57 Absent 33.3 3.5 g/day Mild Prednisone (45 mg Qd) CR, but relapsed
Open in a new tab

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Bid, twice daily; CO, corticosteroid; Cr, creatinine; CR, complete response; CsA, cyclosporin; F, female; HBV, hepatitis B virus; HCQ, hydroxychloroquine; M, male; m, month; MCTD, mixed connective tissue disease; MM, multiple myeloma; MMF, mycophenolate mofetil; NR, not reported; NS, nephrotic syndrome; P, prednisone; PBC, primary biliary cirrhosis; PR, partial response; PSL, prednisolone; pSS, primary Sjogren syndrome; Qd, once daily; RA, rheumatoid arthritis; RTX, rituximab; SIOD, Schimke immune-osseous dysplasia; SLE, systemic lupus erythematosus; SS, Sjogren syndrome; UCTD, undifferentiated connective tissue disease; w, week; y, year. * The value was the amount of proteinuria per day, unless specified.

Table 2.

Characteristics of pathological profiles of PIG cases reported in the literature and in this case series.

Case No Sex Age Renal Pathology
IF Staining Hypercellularity Mesangial Deposit GBM Thickening FPE Microspheres Microtubules Dense Deposit LM Manifestations
1 [2] M 31 All negative Absent Mild Present Present Present Absent Absent MGA
2 [2] F 37 G, A, C3, C1q Absent Mild Present Present Present Present Absent LN Class II
3 [2] F 40 G, A, C3, C1q NR Mild Present Present Present Present Absent LN Class II
4 [2] F 30 G, A, C3, C1q, C5b-9 Present Mild Present Present Present Absent Mesangium, subendothelial LN Class II
5 [2] F 61 G, M, C1q Absent Mild Present Present Present Absent Present LN Class II
6 [2] F 29 All negative Absent Absent Present Present Present Present Absent MN
7 [2] F 46 All negative Absent Absent Present Present Present Present Absent MN
8 [2] F 27 G, A, M, C3, C1q, C5b-9 Absent Absent Present Present Present Present GBM, subendothelial, subepithelial LN Class V
9 [2] M 53 All negative Absent Absent Present Present Present Present Absent MN
10 [2] F 23 G Present Mild Present Present Present Present GBM, subendothelial, subepithelial LN Class V
11 [2] F 31 G Absent Absent Present Present Present Present GBM LN Class V
12 [2] F 24 G, M, C1q Mild Mild Present Present Present Present GBM LN Class V
13 [2] M 49 G, A Present Present Present Present Absent Present Absent MPGN (Type 3)
14 [2] F 20 G Absent Absent Present NR Present Absent GBM MGA
15 [2] F 47 G, A, M Absent Absent Present NR Present Absent GBM MGA
16 [2] F 51 All negative Absent Absent Present Present Present Absent Absent MGA
17 [2] F 30 G Absent Absent Present Present Present Absent Absent MGA
18 [2] F 54 All negative Present Present Present Present Present Absent Absent FSGS
19 [2] F 57 All negative Absent Absent Present Present Present Absent Absent FSGS
20 [2] M 45 G, A, C3 Absent Present Present Present Present Present Absent FSGS
21 [2] F 42 G Present Absent Present Present Present Absent Absent FSGS + MN
22 [2] F 69 G, A, M, C3 Absent Absent Present Present Present Absent Absent MN
23 [2] M 46 G Absent Absent Present Present Present Present Absent MN
24 [2] M 59 M Absent Absent Present Present Present Absent Absent MN
25 [2] F 45 G, A, C3 Absent Absent Present Present Present Present Absent MN
26 [3] M 4 All negative NR NR Present Present Present Absent Absent Focal or global sclerosis
27 [4] F 61 M, C3 Present Present Present Present Present Absent Absent LN
28 [5] F 45 G, C3 Absent Absent Present Present Present Absent Absent MN
29 [6] F 33 M, G, C1q, C3 Mild Mild Present Present Present Absent Mesangium, subepithelial Proliferative glomerulonephritis
30 [7] F 27 M Present Mild Present Present Present Absent Absent Chronic interstitial nephritis
31 [7] F 23 M Absent Absent Present Present Present Absent Absent MGA
32 [8] F 14 M, C3, C1q Absence Absence Absent Presence Present Absent Absent FSGS
33 [9] F 44 M Absent Absent Present Present Present Present Mesangium, intramembrane MGA
34 [11] F 52 All negative Absent Absent Absent Present Present Present Absent Global and segmental sclerosis
35 [12] F 52 All negative NR NR Present Present Present Absent Absent MGA
36 [13] M 79 All negative Absent Absent Present Present Present Absent Absent MN
37 [14] F 38 All negative Absent Present Present Present Present Present Absent FSGS
38 [15] F 35 Full house pattern, faint IgG Present Mild Present Present Present Present Mesangium LN Class II
39 [16] F 60 G, M, A, C3, PLA2r Absent Mild Absent Present Present Present Subepithelial MN
40 [17] F 56 All negative Absent Absent Present Present Absent Absent Absent Acute tubular injury
41 F 26 G, M Mild Present Present Present Present Absent Present FSGS
42 M 47 G Mild Absent Present Present Present Absent Absent FSGS
43 F 48 A, M None Present Present Present Present Absent Absent MN
44 F 57 All negative Absent Mild Mild Present Present Present Absent MGA
Open in a new tab

Abbreviations: A, IgA; F, female; FPE, foot process effacement; FSGS, focal segmental glomerular sclerosis; G, IgG; GBM, glomerular basement membrane; IF, immunofluorescent; LM, light microscopy; LN, lupus nephritis; M, male; M (in IF staining column), IgM; MGA, mild glomerular abnormality; MN, membranous nephropathy; MPGN, membranous proliferative glomerulonephritis; NR, not reported.

Among these 44 cases, 79.5% (35/44) were females, 93.2% (41/44) were East Asians, and 63.6% (28/44) were reported in Japan (see Figure S1). The average age was 42.0 ± 12.5 years old. At the time of renal biopsy, the median (interquartile range) serum creatinine level was 61.9 (52.3) μmol/L, and the average amount of proteinuria was 3.06 ± 3.2 g/day.

An analysis of clinical profiles of these cases indicated the most reported comorbidities were connective tissue diseases, mainly systemic lupus erythematosus (see Figure S2), and 20.5% (9/44) of the cases did not have any contaminant disease. Hematuria was not common. Most of the cases (81.8%, 36/44) were treated with immunosuppressants, of which a combination of corticosteroids and one other type of immunosuppressant was most reported. Furthermore, 45.4% (20/44) and 34.1% (15/44) of the cases have achieved complete response and partial response, respectively, after treatment.

An analysis of the histological profiles of renal biopsies indicated 31.8% (14/44) of the cases were all negative for immunofluorescence (IF) staining (see Figure S3). The most seen deposit on IF staining was IgG. Dense deposits on electron microscopy were not common and only seen in 27.2% (12/44) of the cases.

3. Discussion

Here we reported the largest case series of PIG from a single center so far. The pooled analysis of our cases and the cases in the literature indicated PIG was seen in relatively young populations, often associated with connective tissue diseases clinically and one or two other glomerulopathies histologically. The outcomes following immunosuppressive treatment were relatively good. We also reported for the first time that mutations in INF2 might be involved in the development of PIG; however, the significance of these results were yet unclear.

PIG is a peculiar and very rare pathological manifestation which lacks commonality both clinically and histologically. Although it was proposed as a disease entity in 2008 [2], PIG shows great heterogeneities in multiple aspects. It has been reported in both primary and secondary glomerular diseases and has been observed without any marked glomerular nephropathy. As seen in our literature review, SLE is the most reported comorbidity (17/44, 38.6%) [2,4]. Other connective tissue diseases, such as primary biliary cirrhosis, rheumatoid arthritis, mixed connective tissue disease, and Sjogren syndrome, were also reported [5,6,8,11]. Viral infection was reported in a few cases [2,4]. Membranous nephropathy (MN) and focal segmental glomerular sclerosis (FSGS) were the most common histopathological findings associated with PIG, with 12 and 8 cases reported in the literature and this case series, respectively. There were also a significant proportion of cases that showed only mild glomerular changes. In case three, electron-dense deposits were observed in the thickened GBM, which could be explained by her SLE. This should be differentiated from thickened GBM seen in diabetic nephropathy, smoking and obesity, and when uniform thickening of GBM can also be seen but could be distinguished based on the lack of electron-dense deposits and organized ultrastructure. Thickening of GBM in PIG might be caused by a loss of balance between degradation and biosynthesis of the podocyte matrix [2].

The role of PIG in the pathogenesis of glomerulopathies is still unclear. There are a few hypotheses. For example, it was reported that the formation of PIG might be related to the role of special types of complement activation in situ on the microstructures [18]. Since this phenomenon is a dynamic process from primary infolding to bubbling of podocyte foot processes, which has been observed in serial section electronic microscopy, we also suspected that deficits of cytoskeletal structures might be responsible for this change. The whole exosome sequencing results indicated three of the four cases in our case series carried mutations in INF2, which is a known causative gene of genetic FSGS [19]. INF2 is extensively expressed in renal podocytes, of which the mutations cause the mislocalization of INF2 in podocytes and impaired actin dynamics, subsequently damaging the integrity of the glomerular filtration barrier [20,21,22]. Although our whole exosome sequencing results indicated all four patients carried mutations of INF2, these findings did not support the specifically causative relationship between INF2 mutations and PIG. Future work on potential changes in cytoskeletal structures of podocytes in PIG might help to shed light on this link and will be our next step.

Clinical outcomes of PIG were relatively good. In this review, most cases (34/44, 77.3%) received immunosuppressive treatment consisting of corticosteroids only or with a combination of other immunosuppressants, and nearly 80% (35/44) of the patients had achieved at least partial response. Only less than 5% (2/44) of the patients had shown progression. The coexistence of connective tissue diseases and PIG were the main indications for immunosuppressive treatment. Some patients also received only supportive treatment and had achieved complete or partial response. In our study population, all four patients achieved at least partial response. From this point of view, PIG is relatively benign, even if it is classified as a new disease entity.

To our acknowledge, this is the largest single center case series so far on PIG. PIG is quite heterogenous, both clinically and pathologically. Whether this should be considered as a distinctive disease or merely a pathological representation is inconclusive, according to current understanding. We reported for the first time that mutations in INF2 might be involved in the development of PIG. However, our study also had some limitations. Our genetic sequencing analysis did not include pedigree studies due to travel restrictions caused by COVID-19. In addition, the mutations in INF2 lacked specificity for PIG, preventing us from performing any causative analysis. The clinical significance and underlying mechanisms of PIG need further investigations.

4. Conclusions

PIG is a peculiar and very rare manifestation in renal histopathology. The pathogenesis and clinical significance of PIG are still unclear. This pooled analysis indicated PIG was seen in relatively younger populations, often associated with connective tissue diseases clinically and one or two other glomerulopathies histologically. The outcomes following immunosuppressive treatment were relatively good. Mutations in INF2 might be involved in the development of PIG; however, the implications of these mutations need to be investigated.

Acknowledgments

We sincerely thank the patients and their families as well as the healthcare professionals involved in the patients’ treatment.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12031088/s1, Section S1. Literature review methodology; Figure S1: Demographic characteristics of podocyte infolding cases in literature and this case series report; Figure S2: Clinical characteristics of podocyte infolding cases in literature and this case series report; Figure S3: Histological characteristics of podocyte infolding cases in literature and this case series report.

Click here for additional data file. (418.1KB, zip)

Author Contributions

Conceptualization, Y.F. and P.Z.; data curation, Y.F., W.W. (Wei Wang 1), Y.Z., T.C. and P.Z.; formal analysis, Y.F. and P.Z.; funding acquisition, Y.F.; methodology, Y.F. and W.W. (Wei Wang 2); supervision, G.L.; visualization, Y.Z.; writing—original draft, Y.F. and P.Z.; writing—review and editing, W.W. (Wei Wang 1), T.C., W.W. (Wei Wang 2), G.L. and A.Y.W. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

This study was approved by the ethics committee of Sichuan Provincial People’s Hospital (No. 2017.124). Written informed consent was obtained from the patients for publication of this case series report and any accompanying images. Copies of the written consents to participate in this study from the patients are available for review from the editor of this journal.

Informed Consent Statement

Copies of the written consents to publish this study from the patients are available for review from the editor of this journal.

Data Availability Statement

The data and materials reported in this work are available on reasonable request from the correspondence.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

This research was partly funded by a clinical research grant from Sichuan Provincial People’s Hospital (2020LY02). Y.F. is supported in part by an Australian Government Research Training Program Scholarship (RTP) for study towards a Ph.D. in the Faculty of Medicine, UNSW, Australia. A/Prof Amanda Y Wang is supported by the National Heart Foundation Vanguard Grant, Australia.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Sato H., Saito T., Yoshinaga K. Intramembranous fine deposit disease associated with collagen disorders: A new morphological entity? Virchows Arch A. 1992;420:447–451. doi: 10.1007/BF01600517. [DOI] [PubMed] [Google Scholar]
  • 2.Joh K., Taguchi T., Shigematsu H., Kobayashi Y., Sato H., Nishi S., Katafuchi R., Nomura S., Fujigaki Y., Utsunomiya Y., et al. Proposal of podocytic infolding glomerulopathy as a new disease entity: A review of 25 cases from nationwide research in Japan. Clin. Exp. Nephrol. 2008;12:421–431. doi: 10.1007/s10157-008-0104-z. [DOI] [PubMed] [Google Scholar]
  • 3.Xiong S., Shuai L., Li X., Dang X., Wu X., He Q. Podocytic infolding in Schimke immuno-osseous dysplasia with novel SMARCAL1 mutations: A case report. BMC Nephrol. 2020;21:170. doi: 10.1186/s12882-020-01809-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Liu X., Huang J., Zhang K., Niu Y., Liu Y., Cui C., Yu C. A case of Podocytic Infolding Glomerulopathy with SLE and literature review. BMC Nephrol. 2021;22:410. doi: 10.1186/s12882-021-02615-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Matthai S.M., Mohapatra A., Mathew A.J., Roy S., Varughese S., Danda D., Tamilarasi V. Podocyte Infolding Glomerulopathy (PIG) in a Patient with Undifferentiated Connective Tissue Disease: A Case Report. Am. J. Kidney Dis. 2018;72:149–153. doi: 10.1053/j.ajkd.2017.11.023. [DOI] [PubMed] [Google Scholar]
  • 6.Shi J., Zheng R., Gao H., Zhao Z., Wu H., Zhang Z. Podocyte infolding glomerulopathy with undifferentiated connective tissue disease: A case report. Ultrastruct. Pathol. 2020;44:245–248. doi: 10.1080/01913123.2020.1739791. [DOI] [PubMed] [Google Scholar]
  • 7.Zhang T., Sun W., Xue J., Chen J., Jiang Q., Mou L., Du H. Podocytic infolding glomerulopathy: Two new cases with connective tissue disease and literature review. Clin. Rheumatol. 2019;38:1521–1528. doi: 10.1007/s10067-019-04504-6. [DOI] [PubMed] [Google Scholar]
  • 8.Iguchi A., Sohma A., Yamazaki H., Ito T., Saeki T., Ito Y., Imai N., Osawa Y., Narita I. A case of podocytic infolding glomerulopathy with focal segmental glomerulosclerosis. Case Rep. Nephrol. Urol. 2013;3:110–116. doi: 10.1159/000354591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kwon K.W., Jeong H.J., Lee J.H. Podocytic infolding glomerulopathy: A case report. Ultrastruct. Pathol. 2016;40:374–377. doi: 10.1080/01913123.2016.1229703. [DOI] [PubMed] [Google Scholar]
  • 10.Ou J., Zhu L.J. trackViewer: A Bioconductor package for interactive and integrative visualization of multi-omics data. Nat. Methods. 2019;16:453–454. doi: 10.1038/s41592-019-0430-y. [DOI] [PubMed] [Google Scholar]
  • 11.Ting J.A., Hung W., McRae S.A., Barbour S.J., Copland M., Riazy M. Podocyte Infolding Glomerulopathy, First Case Report from North America. Can J. Kidney Health Dis. 2021;8:20543581211048357. doi: 10.1177/20543581211048357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fang J.Y., Song A.H., Shen B., Liu Y.L. A Case of Podocytic Infolding Glomerulopathy with Primary Sjogren’s Syndrome and Hashimoto’s Thyroiditis. Chin. Med. J. 2018;131:2747–2748. doi: 10.4103/0366-6999.245276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Harada M., Kamijo Y., Ehara T., Shimojo H., Shigematsu H., Higuchi M. A case of podocytic infolding glomerulopathy with multiple myeloma. BMC Nephrol. 2014;15:32. doi: 10.1186/1471-2369-15-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Malvar A., Davila P., Ferrari M., Delgado P., Iscoff P., Lococo B., Alberton V. Podocyte infolding glomerulopathy; report of the first case in Latin America and review of the literature. Nefrologia. 2020;40:469–473. doi: 10.1016/j.nefro.2019.09.010. [DOI] [PubMed] [Google Scholar]
  • 15.Manabe S., Sato M., Kataoka H., Taneda S., Mochizuki T., Nitta K. Cell invasion in glomerular basement membrane: Infolding glomerulopathy. Kidney Int. 2020;98:1623. doi: 10.1016/j.kint.2020.04.035. [DOI] [PubMed] [Google Scholar]
  • 16.Pandit A.P., Rennke H.G., Denker B.M. Podocytic Infolding Glomerulopathy in a Patient with Phospholipase A2 Receptor-Positive Membranous Nephropathy and Review of the Literature. Nephron. 2021;145:496–502. doi: 10.1159/000515769. [DOI] [PubMed] [Google Scholar]
  • 17.Wostmann F., Muller R.U., Gobel H., Benzing T. Becker JU, Bartram MP: Case report: A peculiar glomerulopathy in a patient suffering from nephrotic syndrome. BMC Nephrol. 2019;20:326. doi: 10.1186/s12882-019-1478-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hinglais N., Kazatchkine N.D., Bhakdi S., Appay M.-D., Mandet C., Grossetete J., Bariety J. Immunohistochemical study of the C5d-9 complex of complement in human kidneys. Kidney Int. 1986;30:399–410. doi: 10.1038/ki.1986.198. [DOI] [PubMed] [Google Scholar]
  • 19.Subramanian B., Chun J., Perez-Gill C., Yan P., Stillman I.E., Higgs H.N., Alper S.L., Schlondorff J.S., Pollak M.R. FSGS-Causing INF2 Mutation Impairs Cleaved INF2 N-Fragment Functions in Podocytes. J. Am. Soc. Nephrol. 2020;31:374–391. doi: 10.1681/ASN.2019050443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhao Y., Zhang H., Wang H., Ye M., Jin X. Role of formin INF2 in human diseases. Mol. Biol. Rep. 2022;49:735–746. doi: 10.1007/s11033-021-06869-x. [DOI] [PubMed] [Google Scholar]
  • 21.Panzer L., Trube L., Klose M., Joosten B., Slotman J., Cambi A. Linder S: The formins FHOD1 and INF2 regulate inter- and intra-structural contractility of podosomes. J. Cell Sci. 2016;129:298–313. doi: 10.1242/jcs.177691. [DOI] [PubMed] [Google Scholar]
  • 22.Krendel M., Pruyne D. New Paradigm for Cytoskeletal Organization in Podocytes: Proteolytic Fragments of INF2 Formin Function Independently of INF2 Actin Regulatory Activity. J. Am. Soc. Nephrol. 2020;31:235–236. doi: 10.1681/ASN.2019121292. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (418.1KB, zip)

Data Availability Statement

The data and materials reported in this work are available on reasonable request from the correspondence.

Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES